指南与共识主动脉疾病

胸降主动脉疾病管理:心血管指南间的异同

Management of Descending Thoracic Aortic Diseases: Similarities and Differences Among Cardiovascular Guidelines.
指南 / 共识 · J Endovasc Ther · 2021-01-13

该系统综述检索MEDLINE、EMBASE和Cochrane Central Register of Controlled Trials(2009年1月至2020年5月),初检990篇文献,最终纳入5篇心血管学会指南(2010至2020年发表),分析胸降主动脉疾病管理的争议话题,包括诊断、影像、脊髓缺血预防及主要病理的治疗策略。5个学会指南在胸降主动脉疾病管理上存在显著重叠和一致,尤其在夹层和动脉瘤管理中,TEVAR已成为首选治疗,但许多方面仍需强有力证据。

要点

  • 5个心血管学会指南在胸降主动脉疾病管理上高度一致
  • TEVAR在夹层和动脉瘤管理中已确立首选治疗地位
  • 诸多管理方面仍缺乏强有力证据,存在灰色地带

核心结论

  • 5个心血管学会指南在胸降主动脉疾病管理上存在显著重叠和一致
  • 尤其在夹层和动脉瘤管理中,TEVAR已确立首选治疗地位
  • 许多胸降主动脉病理管理方面仍需强有力证据

研究设计与样本

  • 系统综述,检索MEDLINE、EMBASE和Cochrane Central Register of Controlled Trials从2009年1月至2020年5月
  • 初检990篇文献,最终纳入5篇心血管学会指南(2010至2020年发表)

主要发现

  • 分析了急性与慢性B型主动脉夹层、穿透性主动脉溃疡、壁内血肿、胸主动脉瘤、创伤性主动脉损伤的治疗策略
  • 讨论了炎性动脉瘤、主动脉炎和遗传综合征
  • 呈现了一致的和有争议的推荐以及需要进一步研究的灰色地带问题

临床怎么用

  • TEVAR可作为夹层和动脉瘤管理的首选治疗

局限性

  • 许多胸降主动脉病理管理方面缺乏强有力证据

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cardiovascular societies have developed recommendations regarding the management of thoracic aortic diseases. While improvements in treatment have been observed during the past decade in regard to patient selection, thoracic endovascular aortic repair (TEVAR) and associated techniques, and high-volume centralization, the broad expansion of TEVAR has raised considerations about its indications, appropriateness, limitations, and application. The aim of this systematic review was to assess the similarities and differences among current cardiovascular societies' guidelines for the management of thoracic aortic diseases. The MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials were searched from January 2009 to May 2020. The initial search identified 990 articles. After exclusion of duplicate or inappropriate articles, the final analysis included 5 articles from cardiovascular societies published between 2010 and 2020. Selected controversial topics were analyzed, including diagnosis, imaging, spinal cord ischemia prevention, and management of the most important thoracic aortic pathologies. The analysis included data concerning the therapeutic approach in acute and chronic type B aortic dissection, penetrating aortic ulcer, intramural hematoma, thoracic aortic aneurysm, and traumatic aortic injury, as well a discussion of inflammatory aneurysms, aortitis, and genetic syndromes. The review presents consistent and controversial recommendations, as well as "gray zone" issues that need further investigation. There was significant overlap and agreement among the 5 societies regarding the management of thoracic aortic diseases. Especially in dissection and aneurysm management, TEVAR has established its role as the treatment of choice. However, robust evidence is still needed in many aspects of the management of thoracic aortic pathologies.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Spanos K, Nana P, Behrendt CA, et al. Management of Descending Thoracic Aortic Diseases: Similarities and Differences Among Cardiovascular Guidelines. J Endovasc Ther. 2021. PMID: 33435805. doi:10.1177/1526602820987808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。